679 related articles for article (PubMed ID: 10506637)
1. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.
Hensley ML; Schuchter LM; Lindley C; Meropol NJ; Cohen GI; Broder G; Gradishar WJ; Green DM; Langdon RJ; Mitchell RB; Negrin R; Szatrowski TP; Thigpen JT; Von Hoff D; Wasserman TH; Winer EP; Pfister DG
J Clin Oncol; 1999 Oct; 17(10):3333-55. PubMed ID: 10506637
[TBL] [Abstract][Full Text] [Related]
2. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.
Hensley ML; Hagerty KL; Kewalramani T; Green DM; Meropol NJ; Wasserman TH; Cohen GI; Emami B; Gradishar WJ; Mitchell RB; Thigpen JT; Trotti A; von Hoff D; Schuchter LM
J Clin Oncol; 2009 Jan; 27(1):127-45. PubMed ID: 19018081
[TBL] [Abstract][Full Text] [Related]
3. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
4. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology.
Schuchter LM; Hensley ML; Meropol NJ; Winer EP;
J Clin Oncol; 2002 Jun; 20(12):2895-903. PubMed ID: 12065567
[No Abstract] [Full Text] [Related]
5. Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy.
Links M; Lewis C
Drugs; 1999 Mar; 57(3):293-308. PubMed ID: 10193684
[TBL] [Abstract][Full Text] [Related]
6. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.
Wiseman LR; Spencer CM
Drugs; 1998 Sep; 56(3):385-403. PubMed ID: 9777314
[TBL] [Abstract][Full Text] [Related]
7. The potential of amifostine: from cytoprotectant to therapeutic agent.
Santini V; Giles FJ
Haematologica; 1999 Nov; 84(11):1035-42. PubMed ID: 10553165
[TBL] [Abstract][Full Text] [Related]
8. Cardioprotective effect of dexrazoxane in patients with breast cancer treated with anthracyclines in adjuvant setting: a 10-year single institution experience.
Testore F; Milanese S; Ceste M; de Conciliis E; Parello G; Lanfranco C; Manfredi R; Ferrero G; Simoni C; Miglietta L; Ferro S; Giaretto L; Bosso G
Am J Cardiovasc Drugs; 2008; 8(4):257-63. PubMed ID: 18690759
[TBL] [Abstract][Full Text] [Related]
9. Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy.
Phillips KA; Tannock IF
J Clin Oncol; 1998 Sep; 16(9):3179-90. PubMed ID: 9738590
[TBL] [Abstract][Full Text] [Related]
10. A review of the use of chemoprotectants in cancer chemotherapy.
Lewis C
Drug Saf; 1994 Sep; 11(3):153-62. PubMed ID: 7811398
[TBL] [Abstract][Full Text] [Related]
11. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.
Venturini M; Michelotti A; Del Mastro L; Gallo L; Carnino F; Garrone O; Tibaldi C; Molea N; Bellina RC; Pronzato P; Cyrus P; Vinke J; Testore F; Guelfi M; Lionetto R; Bruzzi P; Conte PF; Rosso R
J Clin Oncol; 1996 Dec; 14(12):3112-20. PubMed ID: 8955656
[TBL] [Abstract][Full Text] [Related]
12. Current role of chemotherapy protectors in cancer treatment.
Cáceres W; Báez L; Aponte I; Rodríguez N; Maldonado A
Bol Asoc Med P R; 1997; 89(10-12):184-8. PubMed ID: 9577052
[TBL] [Abstract][Full Text] [Related]
13. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology.
J Clin Oncol; 1997 Aug; 15(8):2996-3018. PubMed ID: 9256144
[TBL] [Abstract][Full Text] [Related]
14. Dexrazoxane : a review of its use for cardioprotection during anthracycline chemotherapy.
Cvetković RS; Scott LJ
Drugs; 2005; 65(7):1005-24. PubMed ID: 15892593
[TBL] [Abstract][Full Text] [Related]
15. [Development of cancer chemotherapy. Cytoprotective agents].
Lopez M
Clin Ter; 2001; 152(2):135-43. PubMed ID: 11441524
[No Abstract] [Full Text] [Related]
16. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines.
J Clin Oncol; 1994 Nov; 12(11):2471-508. PubMed ID: 7964965
[TBL] [Abstract][Full Text] [Related]
17. [Cardiac toxicity in cancer therapy].
Łacko A; Włodarska I; Zymliński R; Mazur G; Wróbel T; Gisterek I
Pol Merkur Lekarski; 2002 Jul; 13(73):79-85. PubMed ID: 12362515
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats.
Herman EH; Zhang J; Chadwick DP; Ferrans VJ
Cancer Chemother Pharmacol; 2000; 45(4):329-34. PubMed ID: 10755322
[TBL] [Abstract][Full Text] [Related]
19. WR-2721 (amifostine) infusion in patients with Ewing's sarcoma receiving ifosfamide and cyclophosphamide with mesna: drug and thiol levels in plasma and blood cells, a Pediatric Oncology Group study.
Souid AK; Fahey RC; Dubowy RL; Newton GL; Bernstein ML
Cancer Chemother Pharmacol; 1999; 44(6):498-504. PubMed ID: 10550571
[TBL] [Abstract][Full Text] [Related]
20. Cytoprotective agents used in the treatment of patients with cancer.
Hogle WP
Semin Oncol Nurs; 2007 Aug; 23(3):213-24. PubMed ID: 17693348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]